- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Solara Pharma reported a Q2 FY26 consolidated loss of Rs 10.10 Cr on Rs 313.54 Cr revenue. H1 FY26 saw a Rs 0.42 Cr profit. The company plans to raise Rs 134.99 Cr via its rights issue final call and is progressing with the demerger of its CRAMS & Polymers business.
All announcements from Solara Active Pharma Sciences Limited